Tags

Type your tag names separated by a space and hit enter

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Curr Alzheimer Res 2008; 5(1):83-9CA

Abstract

OBJECTIVE

To evaluate the efficacy and safety of memantine in patients with mild to moderate Alzheimer's disease (AD) receiving cholinesterase inhibitor (ChEI) treatment.

METHODS

Participants (N= 433) with probable AD, Mini-Mental State Exam (MMSE) scores between 10-22 (inclusive), and concurrent stable use of ChEIs (donepezil, rivastigmine, galantamine) were randomized to placebo or memantine (20 mg once daily) for 24 weeks. Primary outcomes were changes from baseline on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and on Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) score. Secondary measures comprised the 23-item Alzheimer Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL(23)), Neuropsychiatric Inventory (NPI), and MMSE.

RESULTS

At the end of the trial, there were no statistically significant differences between the memantine- and placebo group on primary and secondary outcome measures. The incidence of adverse events (AEs) was similar between the two groups, with no AE occurring in more than 5% of memantine-treated patients and at a rate twice that of the placebo group.

CONCLUSIONS

In this trial, memantine did not show an advantage over placebo based on protocol-specified primary or secondary analyses in patients with mild to moderate AD on stable ChEI regimens. There were no significant differences in tolerability and safety between the memantine- and placebo groups.

Authors+Show Affiliations

Alzheimer's Disease Care, Research and Education Program, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14620, USA. Anton_Porsteinsson@urmc.rochester.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18288936

Citation

Porsteinsson, Anton P., et al. "Memantine Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving a Cholinesterase Inhibitor: a Randomized, Double-blind, Placebo-controlled Trial." Current Alzheimer Research, vol. 5, no. 1, 2008, pp. 83-9.
Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83-9.
Porsteinsson, A. P., Grossberg, G. T., Mintzer, J., & Olin, J. T. (2008). Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Current Alzheimer Research, 5(1), pp. 83-9.
Porsteinsson AP, et al. Memantine Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving a Cholinesterase Inhibitor: a Randomized, Double-blind, Placebo-controlled Trial. Curr Alzheimer Res. 2008;5(1):83-9. PubMed PMID: 18288936.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. AU - Porsteinsson,Anton P, AU - Grossberg,George T, AU - Mintzer,Jacobo, AU - Olin,Jason T, AU - ,, PY - 2008/2/22/pubmed PY - 2008/5/7/medline PY - 2008/2/22/entrez SP - 83 EP - 9 JF - Current Alzheimer research JO - Curr Alzheimer Res VL - 5 IS - 1 N2 - OBJECTIVE: To evaluate the efficacy and safety of memantine in patients with mild to moderate Alzheimer's disease (AD) receiving cholinesterase inhibitor (ChEI) treatment. METHODS: Participants (N= 433) with probable AD, Mini-Mental State Exam (MMSE) scores between 10-22 (inclusive), and concurrent stable use of ChEIs (donepezil, rivastigmine, galantamine) were randomized to placebo or memantine (20 mg once daily) for 24 weeks. Primary outcomes were changes from baseline on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and on Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) score. Secondary measures comprised the 23-item Alzheimer Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL(23)), Neuropsychiatric Inventory (NPI), and MMSE. RESULTS: At the end of the trial, there were no statistically significant differences between the memantine- and placebo group on primary and secondary outcome measures. The incidence of adverse events (AEs) was similar between the two groups, with no AE occurring in more than 5% of memantine-treated patients and at a rate twice that of the placebo group. CONCLUSIONS: In this trial, memantine did not show an advantage over placebo based on protocol-specified primary or secondary analyses in patients with mild to moderate AD on stable ChEI regimens. There were no significant differences in tolerability and safety between the memantine- and placebo groups. SN - 1567-2050 UR - https://www.unboundmedicine.com/medline/citation/18288936/Memantine_treatment_in_patients_with_mild_to_moderate_Alzheimer's_disease_already_receiving_a_cholinesterase_inhibitor:_a_randomized_double_blind_placebo_controlled_trial_ L2 - http://www.eurekaselect.com/82286/article DB - PRIME DP - Unbound Medicine ER -